Connor, Clark & Lunn Investment Management Ltd. Glycomimetics Inc Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$2.55 - $3.49 $95,441 - $130,623	37,428 Added 26.11%	180,787 $542,000
Q4 2023 Feb 09, 2024	SELL	$1.13 - $2.54 $6,494 - $14,597	-5,747 Reduced 3.85%	143,359 $338,000
Q3 2023 Nov 13, 2023	SELL	$1.29 - $1.73 $9,139 - $12,257	-7,085 Reduced 4.54%	149,106 $223,000
Q2 2023 Aug 10, 2023	SELL	$1.21 - $2.08 $3,400 - $5,844	-2,810 Reduced 1.77%	156,191 $271,000
Q1 2023 May 09, 2023	BUY	$1.25 - $4.05 $117,141 - $379,537	93,713 Added 143.54%	159,001 $200,000
Q4 2022 Feb 10, 2023	BUY	$0.57 - $3.03 $37,214 - $197,822	65,288 New	65,288 $197,000
Q2 2022 Aug 05, 2022	SELL	$0.54 - $1.15 $48,560 - $103,414	-89,926 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.0 - $1.58 $29,469 - $46,561	-29,469 Reduced 24.68%	89,926 $103,000
Q4 2021 Feb 10, 2022	BUY	$1.44 - $2.14 $10,219 - $15,187	7,097 Added 6.32%	119,395 $172,000
Q3 2021 Nov 12, 2021	BUY	$1.8 - $2.39 $10,540 - $13,995	5,856 Added 5.5%	112,298 $246,000
Q2 2021 Aug 12, 2021	SELL	$2.16 - $3.18 $46,411 - $68,328	-21,487 Reduced 16.8%	106,442 $247,000
Q1 2021 May 13, 2021	SELL	$2.89 - $4.22 $1,020 - $1,489	-353 Reduced 0.28%	127,929 $385,000
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $40,855 - $64,397	15,188 Added 13.43%	128,282 $482,000
Q3 2020 Nov 12, 2020	BUY	$3.07 - $5.0 $58,879 - $95,895	19,179 Added 20.42%	113,094 $347,000
Q2 2020 Aug 13, 2020	SELL	$2.06 - $3.76 $75,754 - $138,270	-36,774 Reduced 28.14%	93,915 $353,000
Q1 2020 May 13, 2020	SELL	$1.83 - $5.41 $3,497 - $10,338	-1,911 Reduced 1.44%	130,689 $297,000
Q4 2019 Feb 12, 2020	SELL	$4.03 - $6.5 $3,627 - $5,850	-900 Reduced 0.67%	132,600 $701,000
Q3 2019 Nov 13, 2019	BUY	$2.8 - $12.85 $373,800 - $1.72 Million	133,500 New	133,500 $575,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account